Open-Label Study to Investigate the Mass Balance and Absolute Bioavailability of a Single Oral Dose of [14C]-Labeled RO7049389 or RO7049389 and an Intravenous Micro-Dose of [13C]-Labeled RO7049389 in Healthy Volunteers
Latest Information Update: 22 Jul 2024
Price :
$35 *
At a glance
- Drugs Linvencorvir (Primary) ; Linvencorvir (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors Roche
- 21 Jul 2021 Status changed from active, no longer recruiting to completed.
- 09 Jun 2021 Planned End Date changed from 26 May 2021 to 19 Jun 2021.
- 09 Jun 2021 Planned primary completion date changed from 26 May 2021 to 19 Jun 2021.